--- title: 'Life Sciences Daily Summary: What Happened on October 14, 2026' headline: BioNTech cancer vaccine misses a key trial endpoint description: The day also brought a $135 million biotech financing, two drug-discovery deals and the UK regulator’s plans through 2030. url: https://thebench.bio/news/summaries/2026-10-14 topic: all date: '2026-10-14' covers: - '2026-10-14' date_published: '2026-10-14T12:03:55Z' date_modified: '2026-10-14T12:03:55Z' tags: - Industry - Clinical - Regulatory - Software sources: 8 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on October 14, 2026 **BioNTech cancer vaccine misses a key trial endpoint** The day also brought a $135 million biotech financing, two drug-discovery deals and the UK regulator’s plans through 2030. ## Today in brief In AHEAD-MERIT, BNT113 with pembrolizumab failed to significantly improve progression-free survival, but the Phase 2/3 study will continue to assess overall survival. [1] [2] The UK’s Medicines and Healthcare products Regulatory Agency plans to speed some reviews and use more real-world data and AI to spot potential safety issues. [3] Soufflé Therapeutics secured $135 million for three drug candidates, and Pfizer and Enodia agreed to a Sec61 discovery deal with more than $500 million in potential payments. [4] [5] Generate Biomedicines will research protein medicines for obesity and other metabolic diseases with Zealand Pharma, which agreed to pay $30 million at the outset. The deal includes nearly $1.2 billion in potential milestones. [6] ## BioNTech’s BNT113 misses progression-free survival endpoint BNT113 plus pembrolizumab did not significantly improve progression-free survival over pembrolizumab alone in the AHEAD-MERIT Phase 2/3 trial. [1] [2] The trial tests the combination as an initial treatment for certain people with HPV16-positive head and neck cancer. [1] Progression-free survival was one of the trial’s two primary endpoints, and the data monitoring committee recommended continuing the study to assess overall survival, the other primary endpoint. [2] Under the planned statistical design, a significant overall-survival benefit could still count as a positive trial outcome. [2] BNT113 is an off-the-shelf messenger RNA vaccine encoding HPV16 proteins intended to prompt T cells to attack cancer cells. [1] ## MHRA sets out UK regulatory plans through 2030 The Medicines and Healthcare products Regulatory Agency published a strategy covering medicines, medical devices, clinical research and AI-enabled health technologies through 2030. [3] The agency plans to expand its use of real-world data and AI analysis to identify possible safety issues sooner. [3] For a higher-tier scientific-advice service, the MHRA aims to cut its turnaround from 90 days to 45 days. [3] It also plans to halve the initial assessment target for qualifying Phase 1 trials to 14 days, establish a center focused on AI and digital health, and publish an action plan on AI in medicines development in 2027. [3] The strategy includes plans to increase diversity in clinical studies and introduce a Women’s Health Plan during the year. [3] ## Soufflé raises $135 million for three programs Soufflé Therapeutics secured $135 million to advance three drug candidates toward clinical testing. [4] The programs target facioscapulohumeral muscular dystrophy, or FSHD, heart failure, and muscle and metabolic disorders. [4] ## Pfizer and Enodia team up on Sec61 inhibitors Pfizer and Enodia Therapeutics agreed to discover and develop small-molecule inhibitors of Sec61, a cellular protein channel involved in producing other proteins. [5] [7] Enodia will lead early discovery work across multiple targets, and Pfizer is set to take over clinical trials, manufacturing, regulatory submissions and commercialization after that phase. [5] [8] The agreement could be worth more than $500 million, including an upfront payment, research and development milestones, sales milestones and royalties. [5] [7] [8] Enodia’s internal Sec61 pipeline focuses mainly on immunology, oncology and inflammation, with possible applications in virology. [5] ## Zealand puts $30 million upfront into AI-designed obesity drug research Zealand Pharma will pay Generate Biomedicines $30 million at the outset to research protein medicines for obesity and other metabolic diseases. [6] The deal covers two initial research programs and gives Zealand an option to add a third. [6] Generate may receive up to $35 million in early preclinical milestones and nearly $1.2 billion in total milestone payments, plus tiered royalties. [6] Generate will lead research through candidate selection, after which Zealand will handle clinical development, regulatory submissions and commercialization worldwide. [6] ## The day in numbers - **$135 million**: Funding Soufflé Therapeutics secured to advance three drug candidates toward clinical testing. [4] - **45 days**: The MHRA’s planned turnaround for scientific advice through a higher-tier service, down from 90 days. [3] - **14 days**: The MHRA’s planned initial assessment target for qualifying Phase 1 trials. [3] - **$30 million**: Zealand’s upfront payment to Generate for two initial protein-drug research programs. [6] ## Sources 1. [BioNTech’s mRNA cancer vaccine misses Phase 2/3 endpoint](), European Biotechnology, 2026-10-14 2. [BioNTech misses PFS endpoints in Phase II/III cancer vaccine trial](), Clinical Trials Arena, 2026-10-13 3. [MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines](), MHRA, 2026-10-14 4. [Soufflé Therapeutics snags $135m to bring trio of drugs to the clinic ](), Pharmaceutical Technology, 2026-10-14 5. [Pfizer partners with Enodia Therapeutics in $500m drug deal](), Pharmaceutical Technology, 2026-10-14 6. [Zealand taps Generate’s AI discovery engine in $1.2B obesity deal](), European Biotechnology, 2026-10-14 7. [Enodia lands $500M Pfizer deal to target proteins at the point of synthesis](), European Biotechnology, 2026-10-13 8. [Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules](), GEN, 2026-10-13 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: [7]: [8]: